Abstract:Background: Poor trafficking, exhaustion and low persistence of adoptively transferred T and NK cell-based therapies in solid tumors remain major barriers in the field. Leveraging safety, tumor tropism and ease of genetic manipulation in bacteria present potentially a novel approach to overcome these barriers. Prior approaches to bacteria-based biologics delivery encounter issues of low concentration and fast clearance. In this study, we hypothesized that displaying immune-activating cytokines on outer membrane of Escherichia coli (E. coli) could modulate immunosuppressive tumor microenvironment (TME) enhancing migration, activation, and tumor control mediated by T and natural killer (NK) cells. Methods: To investigate our hypothesis, we expressed human and murine cytokines: IL-15, decoy resistant IL-18 (DR-18), and IL-21 on outer membrane of a non-pathogenic facultative bacteria E. coli K-12. We first evaluated their ability to activate human mesothelin (MSLN) NK cell CARs in vitro and performed gene expression analysis. For the in vivo experiments we used C57BL/6 mouse model with syngeneic tumor cell lines MC38 and B16F10. We also assessed the ability of human cytokine-displaying bacteria with human MSLN-CAR NK cells in NSG mice carrying human mesothelioma H226. Results: OmpA displaying murine DR-18 on bacterial surface was most effective in tumor control. After optimization, intra-tumoral injection of the bacteria resulted in 50% of cured mice bearing MC38 and 30% of cured mice bearing B16F10. Rechallenging these mice with respective cells showed no tumor growth, indicating induction of tumor-specific immune memory. Tumor tissue analysis showed upregulation of CD8 T and NK cells and depletion experiments demonstrated the contribution of these cells to tumor control. When systemically injected, the bacteria inhibited tumor growth with no side effects. Bio-distribution analysis demonstrated bacterial enrichment in TME. Through the utilization of in vitro killing assays by NK cells, YiaT232 scaffold with human DR-18 emerged as the optimal candidate. RNA-sequencing demonstrated that bacteria with DR-18 were capable of upregulating IL-12 and oxidative phosphorylation pathway in NK cells. Furthermore, administration of bacteria displaying DR-18 and systemic (IV) MSLN-CAR-NK cells led to better tumor control (vs soluble DR-18 or bacteria alone) in NSG mice carrying mesothelin-high H226. Conclusions: Here we develop a novel platform for immunotherapy involving surface display of cytokines in non-pathogenic E. coli. The bacteria were safe and demonstrated tumor tropism and CD8 T and NK cells were identified as the major effector cells mediating tumor control in immune-competent mice. Subsequently, we could display human DR-18 on these bacteria which resulted in superior tumor control in NSG mice when combined with MSLN-CAR-NK cells, paving the way for clinical translation in the near future. Citation Format: Shaobo Yang, Michal Sheffer, Isabel Kaplan, Zongqi Wang, Mubin Tarannum, Roman Shapiro, Yasmin Abdulhamid, Rebecca Porter, David Barbie, Robert Soiffer, Jessica Little, Jerome Ritz, Mengdi Yang, Valeria Márquez-Pellegrin, Jiahe Li, Rizwan Romee. Nonpathogenic E. coli engineered to surface display human cytokines for enhanced immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3608.

Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies

Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies

Spatiotemporal Delivery of Dual Nanobodies by Engineered Probiotics to Reverse Tumor Immunosuppression via Targeting Tumor-Derived Exosomes

Engineered probiotic E.coli Nissle 1917 for release PTEN to improve the tumor microenvironment and suppress tumor growth

Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut

Self-adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery

Chemically Enhanced Live Probiotic for in Vivo Tumor Targeting and Inhibition

Probiotic neoantigen delivery vectors for precision cancer immunotherapy

Combinatorial leaky probiotic for anticancer immunopotentiation and tumor eradication

“Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug”

Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors

A Bioorthogonal Probiotic Platform Spatiotemporally Releases Nanobodies in Deep Tumor for Cancer Chemoimmunotherapy

An Engineered Probiotic Platform for Cancer Epitope-Independent Targeted Radionuclide Therapy of Solid Tumors

Engineering Clinically Relevant Probiotics with Switchable "nano‐promoter" and "nano‐effector" for Precision Tumor Therapy

Expressing Cytotoxic Compounds in Escherichia Coli Nissle 1917 for Tumor-Targeting Therapy.

Abstract 6525: Colon cancer screening and treatment with engineered probiotics

Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy

Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy

Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy

Abstract 3608: Nonpathogenic E. coli engineered to surface display human cytokines for enhanced immunotherapy